PROCEPT BioRobotics Corporation (NASDAQ:PRCT – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the nine ratings firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $73.2222.
A number of equities analysts recently issued reports on PRCT shares. Oppenheimer raised shares of PROCEPT BioRobotics from a “market perform” rating to an “outperform” rating and set a $60.00 price target for the company in a research note on Tuesday, September 2nd. Wall Street Zen raised shares of PROCEPT BioRobotics from a “sell” rating to a “hold” rating in a research note on Saturday, August 9th. Piper Sandler decreased their target price on shares of PROCEPT BioRobotics from $80.00 to $55.00 and set an “overweight” rating for the company in a research note on Thursday, August 7th. Morgan Stanley decreased their target price on shares of PROCEPT BioRobotics from $71.00 to $68.00 and set an “overweight” rating for the company in a research note on Tuesday, July 15th. Finally, Wells Fargo & Company decreased their target price on shares of PROCEPT BioRobotics from $75.00 to $58.00 and set an “overweight” rating for the company in a research note on Thursday, August 7th.
Get PROCEPT BioRobotics alerts:
Check Out Our Latest Report on PRCT
PROCEPT BioRobotics Price Performance
PRCT stock opened at $37.14 on Wednesday. PROCEPT BioRobotics has a 1 year low of $36.90 and a 1 year high of $103.81. The company has a market cap of $2.07 billion, a P/E ratio of -23.96 and a beta of 1.03. The firm has a 50-day moving average of $46.77 and a 200 day moving average of $53.62. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.21 and a quick ratio of 7.86.
PROCEPT BioRobotics (NASDAQ:PRCT – Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.06. PROCEPT BioRobotics had a negative net margin of 30.60% and a negative return on equity of 23.73%. The company had revenue of $79.18 million during the quarter, compared to the consensus estimate of $75.67 million. During the same period in the prior year, the firm earned ($0.50) earnings per share. PROCEPT BioRobotics’s revenue was up 48.3% on a year-over-year basis. On average, sell-side analysts forecast that PROCEPT BioRobotics will post -1.75 EPS for the current year.
Hedge Funds Weigh In On PROCEPT BioRobotics
Institutional investors and hedge funds have recently made changes to their positions in the business. ANTIPODES PARTNERS Ltd bought a new position in shares of PROCEPT BioRobotics during the first quarter valued at approximately $30,000. BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of PROCEPT BioRobotics during the first quarter valued at approximately $40,000. Vega Investment Solutions increased its position in shares of PROCEPT BioRobotics by 52.0% during the second quarter. Vega Investment Solutions now owns 775 shares of the company’s stock valued at $45,000 after acquiring an additional 265 shares in the last quarter. CWM LLC increased its position in shares of PROCEPT BioRobotics by 69.5% during the first quarter. CWM LLC now owns 873 shares of the company’s stock valued at $51,000 after acquiring an additional 358 shares in the last quarter. Finally, AlphaQuest LLC increased its position in shares of PROCEPT BioRobotics by 1,262.5% during the second quarter. AlphaQuest LLC now owns 1,090 shares of the company’s stock valued at $63,000 after acquiring an additional 1,010 shares in the last quarter. Institutional investors own 89.46% of the company’s stock.
PROCEPT BioRobotics Company Profile
(Get Free Report)
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).
Featured Stories
Five stocks we like better than PROCEPT BioRobotics
How to Use the MarketBeat Stock Screener
Best Bang For Your Buck? 2 Bargain Stocks with 30%+ Upside
Are Penny Stocks a Good Fit for Your Portfolio?
Football Season Is Here and DraftKings Stock Is Surging
What Are Earnings Reports?
RH Stock Slides After Mixed Earnings and Tariff Concerns